Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
G3 (Bethesda) ; 5(4): 583-92, 2015 Feb 09.
Article in English | MEDLINE | ID: mdl-25670770

ABSTRACT

Population genetic and comparative analyses in diverse taxa have shown that numerous genes involved in reproduction are adaptively evolving. Two genes involved in germline stem cell regulation, bag of marbles (bam) and benign gonial cell neoplasm (bgcn), have been shown previously to experience recurrent, adaptive evolution in both Drosophila melanogaster and D. simulans. Here we report a population genetic survey on eight additional genes involved in germline stem cell regulation in D. melanogaster and D. simulans that reveals all eight of these genes reject a neutral model of evolution in at least one test and one species after correction for multiple testing using a false-discovery rate of 0.05. These genes play diverse roles in the regulation of germline stem cells, suggesting that positive selection in response to several evolutionary pressures may be acting to drive the adaptive evolution of these genes.


Subject(s)
Drosophila/genetics , Germ Cells/metabolism , Stem Cells/metabolism , Animals , Base Sequence , Biological Evolution , DNA Helicases/genetics , Drosophila Proteins/genetics , Evolution, Molecular , Genome , Germ Cells/cytology , Molecular Sequence Data , Polymorphism, Genetic , Stem Cells/cytology
2.
J Clin Invest ; 123(1): 517-25, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23257362

ABSTRACT

Because of the high risk of recurrence in high-grade serous ovarian carcinoma (HGS-OvCa), the development of outcome predictors could be valuable for patient stratification. Using the catalog of The Cancer Genome Atlas (TCGA), we developed subtype and survival gene expression signatures, which, when combined, provide a prognostic model of HGS-OvCa classification, named "Classification of Ovarian Cancer" (CLOVAR). We validated CLOVAR on an independent dataset consisting of 879 HGS-OvCa expression profiles. The worst outcome group, accounting for 23% of all cases, was associated with a median survival of 23 months and a platinum resistance rate of 63%, versus a median survival of 46 months and platinum resistance rate of 23% in other cases. Associating the outcome prediction model with BRCA1/BRCA2 mutation status, residual disease after surgery, and disease stage further optimized outcome classification. Ovarian cancer is a disease in urgent need of more effective therapies. The spectrum of outcomes observed here and their association with CLOVAR signatures suggests variations in underlying tumor biology. Prospective validation of the CLOVAR model in the context of additional prognostic variables may provide a rationale for optimal combination of patient and treatment regimens.


Subject(s)
Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Models, Biological , Ovarian Neoplasms/genetics , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/mortality , Adult , Aged , BRCA1 Protein/biosynthesis , BRCA1 Protein/genetics , BRCA2 Protein/biosynthesis , BRCA2 Protein/genetics , Disease-Free Survival , Female , Humans , Middle Aged , Mutation , Neoplasm Grading , Ovarian Neoplasms/classification , Ovarian Neoplasms/therapy , Predictive Value of Tests , Prospective Studies , Survival Rate
3.
Mol Cell ; 43(1): 57-71, 2011 Jul 08.
Article in English | MEDLINE | ID: mdl-21726810

ABSTRACT

Caspase-2 is an evolutionarily conserved caspase, yet its biological function and cleavage targets are poorly understood. Caspase-2 is activated by the p53 target gene product PIDD (also known as LRDD) in a complex called the Caspase-2-PIDDosome. We show that PIDD expression promotes growth arrest and chemotherapy resistance by a mechanism that depends on Caspase-2 and wild-type p53. PIDD-induced Caspase-2 directly cleaves the E3 ubiquitin ligase Mdm2 at Asp 367, leading to loss of the C-terminal RING domain responsible for p53 ubiquitination. As a consequence, N-terminally truncated Mdm2 binds p53 and promotes its stability. Upon DNA damage, p53 induction of the Caspase-2-PIDDosome creates a positive feedback loop that inhibits Mdm2 and reinforces p53 stability and activity, contributing to cell survival and drug resistance. These data establish Mdm2 as a cleavage target of Caspase-2 and provide insight into a mechanism of Mdm2 inhibition that impacts p53 dynamics upon genotoxic stress.


Subject(s)
Caspase 2/physiology , Cysteine Endopeptidases/physiology , Proto-Oncogene Proteins c-mdm2/metabolism , Tumor Suppressor Protein p53/metabolism , Carrier Proteins/metabolism , Carrier Proteins/physiology , Caspase 2/metabolism , Cisplatin/pharmacology , Cysteine Endopeptidases/metabolism , DNA Damage , Death Domain Receptor Signaling Adaptor Proteins , Feedback, Physiological , Humans
4.
Nature ; 473(7345): 101-4, 2011 May 05.
Article in English | MEDLINE | ID: mdl-21471965

ABSTRACT

Despite the high prevalence and poor outcome of patients with metastatic lung cancer the mechanisms of tumour progression and metastasis remain largely uncharacterized. Here we modelled human lung adenocarcinoma, which frequently harbours activating point mutations in KRAS and inactivation of the p53 pathway, using conditional alleles in mice. Lentiviral-mediated somatic activation of oncogenic Kras and deletion of p53 in the lung epithelial cells of Kras(LSL-G12D/+);p53(flox/flox) mice initiates lung adenocarcinoma development. Although tumours are initiated synchronously by defined genetic alterations, only a subset becomes malignant, indicating that disease progression requires additional alterations. Identification of the lentiviral integration sites allowed us to distinguish metastatic from non-metastatic tumours and determine the gene expression alterations that distinguish these tumour types. Cross-species analysis identified the NK2-related homeobox transcription factor Nkx2-1 (also called Ttf-1 or Titf1) as a candidate suppressor of malignant progression. In this mouse model, Nkx2-1 negativity is pathognomonic of high-grade poorly differentiated tumours. Gain- and loss-of-function experiments in cells derived from metastatic and non-metastatic tumours demonstrated that Nkx2-1 controls tumour differentiation and limits metastatic potential in vivo. Interrogation of Nkx2-1-regulated genes, analysis of tumours at defined developmental stages, and functional complementation experiments indicate that Nkx2-1 constrains tumours in part by repressing the embryonically restricted chromatin regulator Hmga2. Whereas focal amplification of NKX2-1 in a fraction of human lung adenocarcinomas has focused attention on its oncogenic function, our data specifically link Nkx2-1 downregulation to loss of differentiation, enhanced tumour seeding ability and increased metastatic proclivity. Thus, the oncogenic and suppressive functions of Nkx2-1 in the same tumour type substantiate its role as a dual function lineage factor.


Subject(s)
Gene Expression Regulation, Neoplastic , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , Transcription Factors/genetics , Transcription Factors/metabolism , Adenocarcinoma/genetics , Adenocarcinoma/physiopathology , Adenocarcinoma of Lung , Animals , Cell Differentiation , Cell Line, Tumor , Disease Models, Animal , Down-Regulation , HMGA2 Protein/genetics , Humans , Lung Neoplasms/genetics , Lung Neoplasms/physiopathology , Mice , Thyroid Nuclear Factor 1
SELECTION OF CITATIONS
SEARCH DETAIL
...